Top Stories
Seven-year study published in Nature Medicine adds to evidence that GSK's shingles vaccine offer health benefits beyond preventing herpes zoster.
While SPY072 showed statistically significant activity, it didn't meet the company's bar to advance as monotherapy in RA.
Revolution Medicines' oral drug, taken once daily, nearly doubled median overall survival compared to standard chemotherapy in clinical testing.
Partners to jointly advance once-daily oral treatment opakalim towards potential FDA approval in focal epilepsy.
Overall survival benefit in front-line biliary tract cancer marks the first positive readout outside lung cancer for the PD-1/VEGF antibody.
Conference News
Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its p...
NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide.U.S. IRB Approval for P...
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasi...
Roche's deal with Hanmi Pharma adds some validation to an up-and-coming novel target in obesity, potentially getting in ahead of the field's heavy hitters as the bandwagon builds for urocortin-2 (UCN2).
